Claudia Caserta
Modena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.
Journal: Therapeutic advances in medical oncology
Published: January 26, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.
Journal: Cancer immunology, immunotherapy : CII
Published: October 24, 2025
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer.
Journal: Expert review of anticancer therapy
Published: May 21, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study.
Journal: Journal of kidney cancer and VHL
Published: April 12, 2025
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study.
Journal: Clinical genitourinary cancer
Published: July 24, 2024
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer.
Journal: Cancer treatment reviews
Published: February 05, 2024
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Journal: ESMO open
Published: January 11, 2024
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 18, 2023
Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?
Journal: Cancers
Published: August 10, 2022
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Journal: European urology
Published: August 02, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 15, 2022
Last Updated: 09/26/2026